Sign in
Not yet recruitingPhase 2

Gecacitinib Plus Luspatercept in Patients With Myelofibrosis and Anemia

Key facts

Who runs it
Peking Union Medical College Hospital
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
31 people, planned
Started
Nov 2026
Expected to end
Dec 2029
Type of study
Interventional
Treatments tested
  • Gecacitinib
  • Luspatercept
Record updated
16 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (22)Hide the full registry criteria

Who can take part

  • Age 18 years or older
  • Confirmed primary myelofibrosis according to the 2016 World Health Organization diagnostic criteria, or post-polycythemia vera or post-essential thrombocythemia myelofibrosis according to the International Working Group for Myeloproliferative Neoplasms Research and Treatment diagnostic criteria
  • Intermediate-2 or high-risk disease according to the Dynamic International Prognostic Scoring System (DIPSS) or DIPSS-plus, or intermediate-1-risk disease with hepatosplenomegaly that is unresponsive to existing treatment and requires treatment
  • No previous treatment with a Janus kinase inhibitor
  • Discontinuation of other myelofibrosis treatments, such as interferon or hydroxyurea, immunosuppressants, corticosteroids, and growth factors such as erythropoietin, for at least 2 weeks or 6 half-lives before study treatment
  • Splenomegaly, with the spleen palpable 5 cm below the left costal margin
  • Hemoglobin below 100 g/L, with or without red blood cell transfusion dependence
  • Platelet count of at least 75 × 10\^9/L
  • Absolute neutrophil count of at least 1.0 × 10\^9/L
  • Peripheral blood blasts of 10% or less
  • Eastern Cooperative Oncology Group performance status of 0-2 and a life expectancy of more than 6 months
  • Ability to independently provide written informed consent

Who cannot take part

  • Previous splenectomy
  • Previous treatment with any transforming growth factor-beta ligand inhibitor
  • Clinically significant anemia associated with iron, vitamin B12, or folate deficiency; autoimmune or hereditary hemolytic anemia; gastrointestinal bleeding; or thalassemia
  • Active infection
  • A history of malignancy within the previous 5 years, except for cured basal cell carcinoma of the skin or cervical carcinoma in situ
  • Suspected hypersensitivity to gecacitinib, luspatercept, or drugs of the same class
  • Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study
  • Other serious conditions that, in the investigator's judgment, may affect participant safety or compliance, including:; Uncontrolled diabetes mellitus, with blood glucose above 250 mg/dL or 13.9 mmol/L; Hypertension that cannot be controlled to a systolic blood pressure below 160 mmHg and a diastolic blood pressure below 100 mmHg despite combination antihypertensive treatment; Peripheral neuropathy of grade 2 or higher according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0
  • Significant hepatic or renal dysfunction, or dysfunction of another major organ
  • Pregnancy or breastfeeding, women planning pregnancy during the study, or men with near-term plans to father a child

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Myelofibrosis

About the trial

What the trial wants to find out

This single-center, prospective, single-arm study aims to evaluate the efficacy and safety of gecacitinib combined with luspatercept in patients with myelofibrosis and anemia who have not previously received a Janus kinase inhibitor. Participants will receive oral gecacitinib and subcutaneous luspatercept.

The group in the trial

  • Gecacitinib + LuspaterceptTreatment being tested

    gecacitinib 100 mg orally twice daily, combined with luspatercept at an initial dose of 1.0 mg/kg subcutaneously every 3 weeks

    Treatment: Gecacitinib and Luspatercept

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Gecacitinib Combined With Luspatercept in Patients With Myelofibrosis and Anemia: A Single-center, Prospective, Single-arm Study
Criteria questions
Built from NCT07938580, who can take part
Record updated
16 November 2026